RE: Twitter18 Aug 2023 14:41
I forgot to add, Mo mentioned that a significant new benefit of the programme is they are not just recruiting people for challenge studies, but also for phase 1 trials (and potentially beyond).
For example, many people might not qualify for a challenge study because they already have antibodies to a particular pathogen, or they may have some kind of morbidity that disqualifies them (made up hypothetical examples: asthma, psoriasis, etc).
However, in future, there could be a phase 1 trial that is seeking to establish baseline safety and efficacy on those diseases, and now HVO have a pool of people to contact whom may be willing to participate. That's great for all involved and widens the utility of the programme far beyond challenge studies.
I think this is an area that has been under-appreciated.